Last reviewed · How we verify
Nebivolol Ophthalmic Suspension 1 Percent
Nebivolol Ophthalmic Suspension 1 Percent is a Small molecule drug developed by Betaliq, Inc.. It is currently in Phase 2 development.
At a glance
| Generic name | Nebivolol Ophthalmic Suspension 1 Percent |
|---|---|
| Sponsor | Betaliq, Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Nebivolol Ophthalmic Suspension 1 Percent CI brief — competitive landscape report
- Nebivolol Ophthalmic Suspension 1 Percent updates RSS · CI watch RSS
- Betaliq, Inc. portfolio CI
Frequently asked questions about Nebivolol Ophthalmic Suspension 1 Percent
What is Nebivolol Ophthalmic Suspension 1 Percent?
Nebivolol Ophthalmic Suspension 1 Percent is a Small molecule drug developed by Betaliq, Inc..
Who makes Nebivolol Ophthalmic Suspension 1 Percent?
Nebivolol Ophthalmic Suspension 1 Percent is developed by Betaliq, Inc. (see full Betaliq, Inc. pipeline at /company/betaliq-inc).
What development phase is Nebivolol Ophthalmic Suspension 1 Percent in?
Nebivolol Ophthalmic Suspension 1 Percent is in Phase 2.